OtherBASIC SCIENCE INVESTIGATIONS
Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma
Susan E. Buckley, Sarah J. Chittenden, Frank H. Saran, Simon T. Meller and Glenn D. Flux
Journal of Nuclear Medicine September 2009, 50 (9) 1518-1524; DOI: https://doi.org/10.2967/jnumed.109.064469
Susan E. Buckley
Sarah J. Chittenden
Frank H. Saran
Simon T. Meller
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 50, Issue 9
September 2009
Whole-Body Dosimetry for Individualized Treatment Planning of 131I-MIBG Radionuclide Therapy for Neuroblastoma
Susan E. Buckley, Sarah J. Chittenden, Frank H. Saran, Simon T. Meller, Glenn D. Flux
Journal of Nuclear Medicine Sep 2009, 50 (9) 1518-1524; DOI: 10.2967/jnumed.109.064469
Jump to section
Related Articles
Cited By...
- Efficacy and Safety of 124I-MIBG Dosimetry-Guided High-Activity 131I-MIBG Therapy of Advanced Pheochromocytoma or Neuroblastoma
- Does Delayed Excretion of Therapeutic 131I-MIBG Interfere with a 123I-MIBG Diagnostic Scan 6 Weeks After the Therapy?
- A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
- Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial